Hemophilia B Pipeline Assessment, 2024 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Amarna therapeutics, Catalyst

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hemophilia B pipeline constitutes key companies continuously working towards developing Hemophilia B treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Hemophilia B Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Hemophilia B Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hemophilia B Market.

Some of the key takeaways from the Hemophilia B Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Hemophilia B treatment therapies with a considerable amount of success over the years.

*
Hemophilia B companies working in the treatment market are Novo Nordisk A/S, Regeneron Pharmaceuticals, Shanghai Belief-Delivery BioMed, Biocad, Pfizer, CSL Behring, Baxalta now part of Shire, Pfizer, ApcinteX Ltd, Novo Nordisk A/S, Staidson (Beijing) Biopharmaceuticals, Genzyme, Suzhou Alphamab, Sanofi, Jiangsu Gensciences lnc., Spark Therapeutics, Inc., Bayer, and others, are developing therapies for the Hemophilia B treatment

*
Emerging Hemophilia B therapies in the different phases of clinical trials are- Nonacog beta pegol, REGV131, BBM-H901, ANB-002, PF-06838435, AAV5-hFIXco-Padua, AskBio009, marstacimab, SerpinPC, Concizumab, STSP-0601, Fitusiran, KN057, Fitusiran, SS109, SPK-8011, BAY2599023 (DTX201), and others are expected to have a significant impact on the Hemophilia B market in the coming years.

*
In March 2024, TiumBio Co., Ltd. (Kosdaq: 321550), a biopharmaceutical company in the clinical stage, dedicated to uncovering and advancing groundbreaking treatments for individuals with rare and untreatable conditions, has revealed its submission of a Clinical Trial Application (CTA) to the Italian Medicines Agency (AIFA) and the Spanish Agency of Medicines and Medical Products (AEMPS). This application aims to kickstart a Phase 1b investigation of TU7710, a new recombinant activated factor VII (rFVIIa) designed for hemophilia patients who develop inhibitors.

*
In July 2023, Administration of doses has commenced in a Phase 2b clinical investigation assessing the safety and effectiveness of SerpinPC, an experimental treatment for hemophilia developed by Centessa Pharmaceuticals. This open-label trial, named PRESent-2 (NCT05789524), is a component of the company's registration process for hemophilia B. The registration program comprises several clinical studies aimed at gathering evidence to facilitate the therapy's approval for individuals affected by this condition.

Hemophilia B Overview

Hemophilia B, also known as Christmas disease, is a rare genetic bleeding disorder caused by a deficiency in clotting factor IX. This deficiency impairs the blood's ability to clot properly, leading to prolonged bleeding episodes, even from minor injuries.

Get a Free Sample PDF Report to know more about Hemophilia B Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/hemophilia-b-pipeline-insight [https://www.delveinsight.com/report-store/hemophilia-b-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Hemophilia B Drugs Under Different Phases of Clinical Development Include:

*
Nonacog beta pegol: Novo Nordisk A/S

*
REGV131: Regeneron Pharmaceuticals

*
BBM-H901: Shanghai Belief-Delivery BioMed

*
ANB-002: Biocad

*
PF-06838435: Pfizer

*
AAV5-hFIXco-Padua: CSL Behring

*
AskBio009: Baxalta now part of Shire

*
marstacimab: Pfizer

*
SerpinPC: ApcinteX Ltd

*
Concizumab: Novo Nordisk A/S

*
STSP-0601: Staidson (Beijing) Biopharmaceuticals

*
Fitusiran: Genzyme

*
KN057: Suzhou Alphamab

*
Fitusiran: Sanofi

*
SS109: Jiangsu Gensciences lnc.

*
SPK-8011: Spark Therapeutics, Inc.

*
BAY2599023 (DTX201): Bayer

Hemophilia B Pipeline Therapeutics Assessment

*
Hemophilia B Assessment by Product Type

*
Hemophilia B By Stage and Product Type

*
Hemophilia B Assessment by Route of Administration

*
Hemophilia B By Stage and Route of Administration

*
Hemophilia B Assessment by Molecule Type

*
Hemophilia B by Stage and Molecule Type

DelveInsight's Hemophilia B Report covers around products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Hemophilia B product details are provided in the report. Download the Hemophilia B pipeline report to learn more about the emerging Hemophilia B therapies [https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Hemophilia B Therapeutics Market include:

Key companies developing therapies for Hemophilia B are - Aptevo, Bayer, BioMarin, Catalyst Biosciences, CSL Behring, GC Pharma, Kaifeng Pharmaceutical, KM Biologics, LFB, Novo Nordisk, Pfizer, Octapharma, Roche, Sanofi, SinoCelltech, Spark Therapeutics, Takeda, UniQure, and others.

Hemophilia B Pipeline Analysis:

The Hemophilia B pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Hemophilia B with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia B Treatment.

*
Hemophilia B key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Hemophilia B Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hemophilia B market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Hemophilia B drugs and therapies [https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hemophilia B Pipeline Market Drivers

*
Increasing prevalence of Hemophilia B disease, increasing R&D on identifying new therapeutic agents are some of the important factors that are fueling the Hemophilia B Market.

Hemophilia B Pipeline Market Barriers

*
However, high cost of treatment and other factors are creating obstacles in the Hemophilia B Market growth.

Scope of Hemophilia B Pipeline Drug Insight

*
Coverage: Global

*
Key Hemophilia B Companies: Novo Nordisk A/S, Regeneron Pharmaceuticals, Shanghai Belief-Delivery BioMed, Biocad, Pfizer, CSL Behring, Baxalta now part of Shire, Pfizer, ApcinteX Ltd, Novo Nordisk A/S, Staidson (Beijing) Biopharmaceuticals, Genzyme, Suzhou Alphamab, Sanofi, Jiangsu Gensciences lnc., Spark Therapeutics, Inc., Bayer, and others

*
Key Hemophilia B Therapies: Nonacog beta pegol, REGV131, BBM-H901, ANB-002, PF-06838435, AAV5-hFIXco-Padua, AskBio009, marstacimab, SerpinPC, Concizumab, STSP-0601, Fitusiran, KN057, Fitusiran, SS109, SPK-8011, BAY2599023 (DTX201), and others

*
Hemophilia B Therapeutic Assessment: Hemophilia B current marketed and Hemophilia B emerging therapies

*
Hemophilia B Market Dynamics: Hemophilia B market drivers and Hemophilia B market barriers

Request for Sample PDF Report for Hemophilia B Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Hemophilia B Report Introduction

2. Hemophilia B Executive Summary

3. Hemophilia B Overview

4. Hemophilia B- Analytical Perspective In-depth Commercial Assessment

5. Hemophilia B Pipeline Therapeutics

6. Hemophilia B Late Stage Products (Phase II/III)

7. Hemophilia B Mid Stage Products (Phase II)

8. Hemophilia B Early Stage Products (Phase I)

9. Hemophilia B Preclinical Stage Products

10. Hemophilia B Therapeutics Assessment

11. Hemophilia B Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Hemophilia B Key Companies

14. Hemophilia B Key Products

15. Hemophilia B Unmet Needs

16 . Hemophilia B Market Drivers and Barriers

17. Hemophilia B Future Perspectives and Conclusion

18. Hemophilia B Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Guarav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hemophilia-b-pipeline-assessment-2024-updates-indepth-insights-into-the-emerging-drugs-latest-fda-ema-and-pmda-approvals-clinical-trials-and-treatment-outlook-amarna-therapeutics-catalyst]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.